PARP inhibitors may have efficacy in selected TNBC patients outside of germline BRCA

[News]

The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways.

More... (https://www.news-medical.net/news/20171101/PARP-inhibitors-may-have-efficacy-in-selected-TNBC-patients-outside-of-germline-BRCA-mutation.aspx)